In preclinical investigations, the TLR9 agonist K3 CpG and the STING agonist 3′3’cGAMP demonstrated a synergistic effect in inducing IFNγ and enhanced CD4+, CD8+ T cell as well as NK cell responses, ultimately suppressing tumor growth in lymphoma and melanoma in vivo.[82] Similarly, the combination of ADU‐S100 with CpG ODN1826 (TLR9 agonist) showed decreased tumor volume and an improved survival rate in a SC CT26 model compared to the PBS control group. Here, TLR9 is linked to neoplasm.